Payment overview · 2025
General Payments
$2,131.88
74 reported records · 15 companies
Healthcare provider profile · identity verified
Doeyoung Kim, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LOS ANGELES, CA · NPI 1093913444
Verified facts
What the public records show
CMS Open Payments records show Doeyoung Kim, MD received $2,131.88 in general payments during 2025 across 74 reported records.
ABBVIE INC. accounted for 16.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Ozempic, Prolia, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 783 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 289 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 283 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 283 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $341.64 | 16.0% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $311.29 | 14.6% | 14 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $244.80 | 11.5% | 10 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $210.86 | 9.9% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $207.37 | 9.7% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $155.70 | 7.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $144.07 | 6.8% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $129.30 | 6.1% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $121.84 | 5.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $116.20 | 5.5% | 5 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $53.36 | 2.5% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $32.57 | 1.5% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $28.21 | 1.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.89 | 0.9% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $15.78 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,131.88 | 74 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $244.80 | 10 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $242.40 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $234.90 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $233.24 | 9 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $210.86 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $155.70 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $129.30 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $121.84 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $106.32 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $106.32 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $101.05 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $100.09 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $76.39 | 3 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $53.36 | 2 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $34.85 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $32.57 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $31.99 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.92 | 1 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $28.21 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.03 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.03 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $15.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 783 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 166 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 66 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 283 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 289 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 77 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 37 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
783 | 158 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
289 | 54 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
77 | 53 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
166 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
283 | 46 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
37 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
283 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
66 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2423 | 441 |
| Losartan Potassium | Losartan Potassium | 1313 | 238 |
| Amlodipine Besylate | Amlodipine Besylate | 1210 | 210 |
| Omeprazole | Omeprazole | 1087 | 244 |
| Vascepa | Icosapent Ethyl | 1058 | 175 |
| Metformin Hcl | Metformin Hcl | 874 | 157 |
| Creon | Lipase/Protease/Amylase | 783 | 158 |
| Tamsulosin Hcl | Tamsulosin Hcl | 617 | 112 |
| Donepezil Hcl | Donepezil Hcl | 582 | 88 |
| Lidocaine | Lidocaine | 570 | 106 |
| Memantine Hcl Er | Memantine Hcl | 555 | 84 |
| Azithromycin | Azithromycin | 496 | 299 |
| Januvia | Sitagliptin Phosphate | 487 | 52 |
| Pantoprazole Sodium | Pantoprazole Sodium | 466 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 449 | 88 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 378 | 69 |
| Icosapent Ethyl | Icosapent Ethyl | 375 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 367 | 57 |
| Gabapentin | Gabapentin | 332 | 68 |
| Baclofen | Baclofen | 321 | 95 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 309 | 120 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 306 | 57 |
| Tradjenta | Linagliptin | 305 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 293 | 57 |
| Linzess | Linaclotide | 289 | 54 |
| Zolpidem Tartrate | Zolpidem Tartrate | 288 | 86 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 284 | 89 |
| Jardiance | Empagliflozin | 283 | 46 |
| Celecoxib | Celecoxib | 281 | 52 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 273 | 65 |
| Ketoconazole | Ketoconazole | 263 | 74 |
| Meloxicam | Meloxicam | 263 | 94 |
| Montelukast Sodium | Montelukast Sodium | 257 | 36 |
| Cyclosporine | Cyclosporine | 239 | 51 |
| Alendronate Sodium | Alendronate Sodium | 236 | 47 |
| Finasteride | Finasteride | 224 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 213 | 37 |
| Restasis | Cyclosporine | 201 | 36 |
| Pioglitazone Hcl | Pioglitazone Hcl | 196 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 187 | 31 |
| Dexlansoprazole Dr | Dexlansoprazole | 185 | 38 |
| Ibandronate Sodium | Ibandronate Sodium | 179 | 35 |
| Ezetimibe | Ezetimibe | 177 | 31 |
| Famotidine | Famotidine | 177 | 39 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 175 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 167 | 45 |
| Farxiga | Dapagliflozin Propanediol | 166 | 24 |
| Pregabalin | Pregabalin | 163 | 20 |
| Diclofenac Epolamine | Diclofenac Epolamine | 161 | 24 |
| Glipizide Er | Glipizide | 161 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 153 | 38 |
| Ursodiol | Ursodiol | 153 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 145 | 24 |
| Metformin Hcl Er | Metformin Hcl | 134 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 25 |
| Tadalafil | Tadalafil | 132 | 20 |
| Eliquis | Apixaban | 131 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 129 | 22 |
| Sertraline Hcl | Sertraline Hcl | 128 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 127 | 21 |
| Carvedilol | Carvedilol | 125 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 125 | 83 |
| Alprazolam | Alprazolam | 122 | 28 |
| Zenpep | Lipase/Protease/Amylase | 121 | 30 |
| Lisinopril | Lisinopril | 119 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 25 |
| Raloxifene Hcl | Raloxifene Hcl | 115 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 114 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 111 | 19 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 109 | 15 |
| Glipizide | Glipizide | 107 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 106 | 14 |
| Furosemide | Furosemide | 103 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 31 |
| Simvastatin | Simvastatin | 92 | 12 |
| Mupirocin | Mupirocin | 91 | 57 |
| Sodium Chloride | 0.9 % Sodium Chloride | 91 | 66 |
| Megestrol Acetate | Megestrol Acetate | 90 | 34 |
| Mirtazapine | Mirtazapine | 90 | 19 |
| Ozempic | Semaglutide | 89 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 87 | 38 |
| Tramadol Hcl | Tramadol Hcl | 85 | 32 |
| Amoxicillin | Amoxicillin | 82 | 63 |
| Allopurinol | Allopurinol | 81 | 12 |
| Atenolol | Atenolol | 81 | 16 |
| Nifedipine Er | Nifedipine | 80 | 14 |
| Cephalexin | Cephalexin | 77 | 60 |
| Prolia | Denosumab | 77 | 53 |
| Latanoprost | Latanoprost | 76 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 75 | 39 |
| Azelastine Hcl | Azelastine Hcl | 73 | 17 |
| Fenofibrate | Fenofibrate | 72 | suppressed |
| Loperamide | Loperamide Hcl | 71 | 41 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 70 | 58 |
| Sildenafil Citrate | Sildenafil Citrate | 70 | 16 |
| Ibuprofen | Ibuprofen | 67 | 33 |
| Metoclopramide Hcl | Metoclopramide Hcl | 67 | 19 |
| Gemtesa | Vibegron | 66 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 65 | 16 |
| Hydrocortisone | Hydrocortisone | 64 | 34 |
| Acyclovir | Acyclovir | 63 | 39 |
| Memantine Hcl | Memantine Hcl | 62 | 12 |
| Temazepam | Temazepam | 58 | 29 |
| Trazodone Hcl | Trazodone Hcl | 58 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 54 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 19 |
| Nitroglycerin | Nitroglycerin | 53 | 22 |
| Clonazepam | Clonazepam | 52 | suppressed |
| Spironolactone | Spironolactone | 52 | 12 |
| Meclizine Hcl | Meclizine Hcl | 51 | 26 |
| Unifine Pentips Plus | Pen Needle, Diabetic | 50 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 49 | suppressed |
| Myrbetriq | Mirabegron | 49 | 11 |
| Clotrimazole | Clotrimazole | 46 | suppressed |
| Ciclopirox | Ciclopirox | 45 | 19 |
| Ciclopirox | Ciclopirox Olamine | 45 | 12 |
| Dutasteride | Dutasteride | 45 | suppressed |
| Lansoprazole | Lansoprazole | 45 | 18 |
| Lorazepam | Lorazepam | 45 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 43 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 42 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 42 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Telmisartan | Telmisartan | 42 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 42 | suppressed |
| Metronidazole | Metronidazole | 41 | 33 |
| Humalog Kwikpen U-100 | Insulin Lispro | 40 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 40 | 39 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Febuxostat | Febuxostat | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Nateglinide | Nateglinide | 38 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 37 | suppressed |
| Fluocinonide | Fluocinonide | 37 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 37 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 35 | suppressed |
| Procto-Med Hc | Hydrocortisone | 34 | 18 |
| Bethanechol Chloride | Bethanechol Chloride | 33 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Kerendia | Finerenone | 32 | suppressed |
| Sucralfate | Sucralfate | 32 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Dexilant | Dexlansoprazole | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Erythromycin | Erythromycin Base | 27 | 17 |
| Glimepiride | Glimepiride | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Xiidra | Lifitegrast | 27 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 26 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 17 |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Rivastigmine | Rivastigmine | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 17 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 18 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 21 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | 12 |
| Prednisone | Prednisone | 20 | 13 |
| Prempro | Estrogen,con/M-Progest Acet | 20 | suppressed |
| Voquezna | Vonoprazan Fumarate | 20 | suppressed |
| Repaglinide | Repaglinide | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 17 |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 17 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Licart | Diclofenac Epolamine | 16 | suppressed |
| Minoxidil | Minoxidil | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | 13 |
| Synjardy | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Exelon | Rivastigmine | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Selenium Sulfide | Selenium Sulfide | 14 | suppressed |
| Triazolam | Triazolam | 14 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 13 |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,131.88 · 74 records | ABBVIE INC. | AIRSUPRA, CREON, EVENITY, FARXIGA, GEMTESA, IBSRELA, JARDIANCE, Kerendia, LEQEMBI, LINZESS, MOUNJARO, OTEZLA, Ozempic, PANCREAZE, PROLIA, Polivy, QULIPTA, REPATHA, REXULTI, SHINGRIX, VERQUVO, VIBERZI, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error